A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2018
Price : $35 *
At a glance
- Drugs SRF 231 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Surface Oncology
- 18 Dec 2018 Results presented in a Surface Oncology media release.
- 18 Dec 2018 According to a Surface Oncology media release, to date, 18 patients have been treated with SRF231 on an every-three-week schedule. An additional SRF231 data is expected in second half on 2019.
- 29 May 2018 According to a Surface Oncology media release, initial clinical results from this trial are expected in the first half of 2019.